drugset / Trial / NCT06939595
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
Timeline
- Start
- 2025-01-30
- Primary completion
- 2027-02
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT-P51 | Unknown | 200 mg | — |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | — |